These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 38152694

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F.
    J Headache Pain; 2024 Feb 02; 25(1):14. PubMed ID: 38308209
    [Abstract] [Full Text] [Related]

  • 3. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A.
    Pain Ther; 2021 Dec 02; 10(2):809-826. PubMed ID: 33880725
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 02; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 7. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ.
    J Headache Pain; 2023 Aug 02; 24(1):101. PubMed ID: 37532991
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G.
    Rev Neurol (Paris); 2020 Dec 02; 176(10):788-803. PubMed ID: 32758365
    [Abstract] [Full Text] [Related]

  • 9. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.
    Eur J Neurol; 2023 Jun 02; 30(6):1764-1773. PubMed ID: 36856538
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH, Lange KS, Fitzek MP, Siebert A, Steinicke M, Triller P, Hong JB, Reuter U, Raffaelli B.
    Front Neurol; 2023 Jun 02; 14():1154420. PubMed ID: 37034092
    [Abstract] [Full Text] [Related]

  • 13. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D.
    J Headache Pain; 2020 Jul 03; 21(1):84. PubMed ID: 32620151
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.
    Lancet Neurol; 2017 Jun 03; 16(6):425-434. PubMed ID: 28460892
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P, Chawla E.
    Clin Neurol Neurosurg; 2021 Oct 03; 209():106893. PubMed ID: 34464833
    [Abstract] [Full Text] [Related]

  • 18. Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years.
    Pons-Fuster E, Lozano-Caballero O, Martín-Balbuena S, Lucas-Ródenas C, Mancebo-González A, De Gorostiza-Frías I, González-Ponce CM.
    Int J Clin Pharm; 2024 Dec 03; 46(6):1317-1326. PubMed ID: 38990457
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P, De Cesaris F.
    CNS Drugs; 2023 Feb 03; 37(2):189-202. PubMed ID: 36656298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.